Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
This is how I see it too... stop loss clean out before news...
Thanks for the dip... picked up 50k more shares sub $0.3...(-:
Considering my initial buy was $0.0051, and I have now averaged down to $0.0019, I'm feeling pretty good about things.... expecting as much as a quarter upon positive lawsuit... I also expect large initial payment plus quarterly royalties going forward, and depending on what HCMC does with those royalties could make this company a real player....
Believe it or not I hope you are right.... I hope it goes to $0.0001.... and when it does I will back the dump truck, pour out the cash, and load the boat with shares....(-:
Thanks Ms Lucy... really appreciate your DD....(-:
Me too... but I don't believe it either...
There is, of course, one exception... BP is behind the shorting... but if so, and they are worried, why isn't the shorting activities more agressive now???
It's not as if they haven't had the time....
Truth...(-:
I look forward to watching your children play.... maybe in Singapore...(-:
We are in agreement...(-:
Management should use a significant amount of the settlement to buy back some of the OS....
Could be wrong, but I believe this is going under $2... maybe below $1 before the shorts are done with us...
Thanks Hook...(-:
God, I hope not.... I remember back to the innocent days when everyone believed it would only take 2 weeks after data lock to get TLD... what a crock!!!
Well... we are in our SIXTH MONTH of waiting for TLD... I assume we will continue this slide until we get it... I sincerely hope the result is worth this hellish wait...
Here is my question: How is it that we get very positive and complimentary press from several sources, including Bloomberg, and instead of the pps going up, it plummets..
I really do not understand...
So what did they say...???
Sorry for the stupid question moneycrew:
What news...???
The other half imho is picking the right stock...(-:
I got 2 words for the FDA:
Andrew Cuomo
And what is MY kind, Sam???
My opinion isn't based on HCMC at all, even though I am in for 21+ million shares (and looking to add)... my opinion is based on holding NWBO for 6 years and watching the share price drop every time he showed up while holding over 700k shares... laugh at yourself.
Never said his chart affects a stock... my belief is that the presence of his chart is a signal to shorts to do their thing on a given day... does that mean it can't be overcome by a bull run??? No... but it may decrease the magnitude of the run...
Not idolizing him... just been in too many stocks where his presence signaled shorting activities.... happened with NWBO for years. Saw the pps go from $12.55 to $0.14 (twice). Now, very close to phase lll reveal and he is nowhere to be found. However... I also believe his presence indicates the big boys think there is value here, which if true is good for everyone that sticks to their guns and holds... if the pps continues to stay down I will add...
Based on CT's appearance, I wouldn't bet too heavy on tomorrow ending up green...(-:
The following is a post copied off the RLFTF board about their product but has a lot of opinions about CYDY... I am curious about any additional opinions from the board members here about this post and the author's conclusions:
"OU36 hours ago
The day has finally come when we have a glimpse of the hyped CD12 RCT readout by CYDY. The results are mixed at best and the bar is set low enough that Zyesami (Aviptadil) can jump over it as the most effective treatment for severe and critical CV19. While the full data reveal is not out for either company, the highlights from CYDY’s Friday press release indicate that at best, CYDY improved outcomes for what appears to apply to a subset of patients. The press release indicates leronlimab improved release from the hospital by 6 days for critical patients. Re reading the release many times this morning, it appears they sugar coated the facts and leronlimab only had an effect for a subset of 62 of the 384 patients. Unsurprising maneuver given CYDY’s management history. Regardless, the remaining results are observational and do not reveal any effect beyond chance. Further studies will be needed to confirm if any of the observational data can prove out to the FDA. It appears from the release CYDY is now scrambling to make that happen with EIND data. Good luck convincing the FDA with non RCT results. A new study will be required and with it they will need additional funding.
As for Zyesami, this week will be crucial, as the pressure is on to see the 60 day results, but interestingly it’s not their only shot to be discovered. The iSpy inhaled study is still in the works and given that Covid is not going away anytime soon according to nearly all the knowledgeable medical advice, I like Zyesami’s chances!
While CYDY may be left for dead trying to fund future trials with an inept executive team and shady financier who is now under serious SEC investigations, Zyesami’s inclusion in the iSpy trial by NIH and plenty of cash by the mothership Relief means Zyesami is very much still in the game.
The most promising fact is that the preliminary results released two weeks ago on Zyesami indicated a medical effect of the drug after 28 days on a subset of HFNC patients. However, there is more to be revealed for Zyesami IV. In fact, my prediction is that Javitt will reveal moderately significant results at 60 days. Why? Because there is a slow down in the progression of the disease due to SOC and this fact masks the results at 28 days. However, my hunch is that after 60 days the differences will be revealed. Add in the the radiographic data (CT Scans) of the lungs, and we will have the ability at the very least to excite the FDA and investors.
The fact remains that this is the first trial ever undertaken with this drug to address CV19 and admittedly Javitt underdosed patients with Zyesami, but Javitt was smart enough to make sure our endpoints were reset and there is enough scientific data included in the trial to detect a “medical signal” (using his words). CYDY did the opposite by not resetting endpoints and firing Dr. Bruce Patterson at IncellDx which excluded his brilliant cellular marker data which would have helped CYDY’s case of detecting a “medical signal” due to the drug. Investors in Zyesami already see signs of this benefit in the EIND results with the compelling lung scan data. While not a primary endpoint for the study, the FDA cares about these medically relevant facts and its unfortunate for CYDY investors that they accepted Nader Pourhassen’s lies to cover up why they kicked Bruce off the team and hurt shareholders!
Lastly, the impact of this drug on Long Haulers (SARS-CoV-2 - PASC) pulmonary issues is the holy grail few are realizing. A vast percentage of long haulers are suffering longterm lung damage and this MAY BE THE ONLY TREATMENT on planet earth that can help them in the FDA pipeline.
? Leronlimab - no
? Other MABs - no
? Arthritis drugs - no
? Synairgen - no,
? EXO-CD24 - no,
? Zyesami - Yes it’s possibly effective for post infection pulmonary recovery.
To recap. I’m disappointed in Leronlimab. It failed it’s primary endpoint which was mortality. If it met it, the press release would have screamed it... it did not. Furthermore, it failed every other secondary unless one subgroup was broken out (62 critical patient in the CYDY study), however this population size is not large enough to convince the FDA regardless of significance..."
There is a 'caste' system in the stock market. The MM's cater to the large corporations who give the MM's tons of money because they make their clients rich (unlike you and me)... best to live with the idea that IF we guess right, we will feast on the scraps, while the large Corps and MM's get the steak and lobster... in a place where money is all that matters, if you don't have BILLIONS, you don't matter. The shorting goes on between MM's like NITE and CDEL, who sell to each other at lower and lower prices, never sacrificing much $$$, while driving the pps down, causing hundreds and thousands of average Joe traders (you and me) to sell his/her investment at a loss because they think the stock is going in the toilet. After they get all they think they can get (for their clients), they will reverse the process, pushing the price up... all you can do as an investor is to hold your shares, buy the dips, and hang on until they start pushing the price back up.... and I doubt we are there yet... {all of the above is just my opinion, of course...(-:}
Answer: more expensive shares...(-:
Well, added some more at $0.0013... just couldn't hold out for $0.0011.... up to 21MM shares now at avg pps of $0.0019... not near as good as some here, but good enough for me...(-:
You can make a lot of money playing ping pong, depending on how long the game lasts...(-:
Showing $0.002 on my TDA.... pre market... but I thought OTC didn't trade pre market... wth???
Been meaning to ask... why Marlin1111...????
Between market correction and 40% taxes on capital gains I am in a funk...
Yep... some genius here said tomorrow was gonna be the bottom... so I was out doing... had planned on doubling my position...)-:
Woah....!!!! It just occurred to me. There is only ONE reason companies convert all their preferred stock and stock options to common stock:
M&A
It makes it easier to figure the net value of the company...
I believe there is going to be a merger with $MJNE....
That really pisses me off, because I couldn't get my paltry 2.75 million share bid filled at $0.0013 for over half the day and had to increase my bid to $0.0014 and of course it was immediately filled...
)-:
Cost me about 175k shares...
/-:«
This should be noted... from the 8-k:
As per the Company’s previous filings, on August 16, 2018, the Company entered into Warrant Exchange Agreements with certain holders of its Series A Warrants to exchange 46,048,318 Series A Warrants for 20,722 shares of Series B Stock. The Series A Warrants acquired by the Company in that exchange represented approximately 92% of the outstanding Series A Warrants and would have been convertible into 460,483,180,000 shares of Company common stock if exercised as of the date of the Warrant Exchange Agreements. This exchange reduced the amount of common stock to be converted from the Series A Warrants from 460,483,180,000 to 207,220,000,000 – an approximate 45% savings in dilution for the company and its common stock shareholders.
Great post... thank you.
You will notice question marks after my post... I was asking...
Maybe not... amazing how they play with the pps...maybe one day soon...
News coming...???